In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B generates $10mm for Anchor Therapeutics

Executive Summary

Anchor Therapeutics Inc. (formerly Ascent Therapeutics; developing pepducin drug candidates that selectively target G protein coupled receptors) has raised $10mm through its Series B financing led by returning shareholders TVM Capital, HealthCare Ventures, and the Novartis Option Fund. The company says that other investors may add money to the round.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies